첨단 치료제 CDMO 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측 : 제품별, 단계별, 적응증별, 지역별, 경쟁별(2020-2030년)
Advanced Therapy Medicinal Products CDMO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Phase, By Indication, By Region and Competition, 2020-2030F
상품코드:1668080
리서치사:TechSci Research
발행일:2025년 02월
페이지 정보:영문 180 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
첨단 치료제 CDMO 세계 시장 규모는 2024년 51억 2,000만 달러로 평가되며, 예측 기간 동안 9.54%의 CAGR로 2030년에는 88억 7,000만 달러에 달할 것으로 예상됩니다.
첨단 치료제 CDMO 세계 시장은 제약 및 생명공학 산업에서 가장 역동적이고 빠르게 발전하고 있는 분야입니다. 이 시장에는 유전자 치료제, 세포 치료제, 조직공학 제품 등을 포함한 첨단치료제(ATMP)의 개발 및 제조를 전문으로 하는 조직이 포함됩니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
51억 2,000만 달러
시장 규모 : 2030년
88억 7,000만 달러
CAGR : 2025-2030년
9.54%
급성장 부문
종양학
최대 시장
북미
시장 촉진요인
첨단 치료제 보급
주요 시장 과제
높은 비용
주요 시장 동향
협업과 파트너십 증가
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 소리
제5장 세계의 첨단 치료제 CDMO 시장 전망
시장 규모 및 예측
금액별
시장 점유율과 예측
제품별(유전자 치료, 세포 치료, 조직공학, 기타)
단계별(단계 I, 단계 II, 단계 III, 단계 IV)
적응증별(종양학, 심장병학, 중추신경계, 근골격계, 감염증, 면역학과 염증, 기타),
지역별
기업별(2024년)
시장 맵
제6장 북미의 첨단 치료제 CDMO 시장 전망
시장 규모 및 예측
시장 점유율과 예측
북미 : 국가별 분석
캐나다
멕시코
제7장 유럽의 첨단 치료제 CDMO 시장 전망
시장 규모 및 예측
시장 점유율과 예측
유럽 : 국가별 분석
영국
이탈리아
프랑스
스페인
제8장 아시아태평양의 첨단 치료제 CDMO 시장 전망
시장 규모 및 예측
시장 점유율과 예측
아시아태평양 : 국가별 분석
인도
일본
한국
호주
제9장 남미의 첨단 치료제 CDMO 시장 전망
시장 규모 및 예측
시장 점유율과 예측
남미 : 국가별 분석
아르헨티나
콜롬비아
제10장 중동 및 아프리카의 첨단 치료제 CDMO 시장 전망
시장 규모 및 예측
시장 점유율과 예측
중동 및 아프리카 : 국가별 분석
사우디아라비아
아랍에미리트
제11장 시장 역학
성장 촉진요인
과제
제12장 시장 동향과 발전
인수합병(해당되는 경우)
제품 발매(해당되는 경우)
제13장 Porter's Five Forces 분석
산업내 경쟁
신규 참여의 가능성
공급업체의 능력
고객의 능력
대체품의 위협
제14장 경쟁 구도
Celonic AG
Rentschler Biopharma SE
Catalent, Inc.
Lonza Group AG
WuXi Advanced Therapies
Minaris Regenerative Medicine, LLC
Pluri BIoTech Ltd.
REPROCELL USA Inc.
BioPhorum Operations Group
Cellares Corporation
제15장 전략적 제안
제16장 조사 회사 소개 및 면책사항
ksm
영문 목차
영문목차
Global Advanced Therapy Medicinal Products CDMO Market was valued at USD 5.12 Billion in 2024 and is expected to reach USD 8.87 Billion by 2030 with a CAGR of 9.54% during the forecast period. The Global Advanced Therapy Medicinal Products CDMO Market is a dynamic and rapidly evolving sector within the pharmaceutical and biotechnology industries. This market encompasses organizations that provide specialized services for the development and manufacturing of advanced therapy medicinal products (ATMPs), which include gene therapies, cell therapies, and tissue-engineered products.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 5.12 Billion
Market Size 2030
USD 8.87 Billion
CAGR 2025-2030
9.54%
Fastest Growing Segment
Oncology
Largest Market
North America
Key Market Drivers
Proliferation of Advanced Therapies
The healthcare landscape is witnessing a revolution as advanced therapies, including gene therapies, cell therapies, and tissue-engineered products, emerge as groundbreaking treatments for previously incurable diseases. This paradigm shift in medicine is driving the demand for specialized services provided by Contract Development and Manufacturing Organizations (CDMOs).
The advent of advanced therapies has expanded therapeutic horizons, offering new hope to patients suffering from rare and debilitating conditions. These therapies target the root causes of diseases at the genetic and cellular levels, promising higher efficacy and fewer side effects compared to traditional treatments. As more conditions become treatable through advanced therapies, the demand for CDMO services to develop and manufacture these products increases.
Pharmaceutical companies, biotechnology firms, and academic institutions are investing heavily in advanced therapy research and development. This surge in investment translates into a growing pipeline of potential therapies. CDMOs are integral to this process, providing the expertise and infrastructure needed to advance these therapies from the laboratory to clinical trials and eventual commercialization.
The development and manufacturing of advanced therapies come with complex regulatory challenges. Regulatory bodies like the FDA and EMA have stringent requirements to ensure the safety and efficacy of these novel treatments. CDMOs specializing in advanced therapies possess the regulatory expertise to help clients navigate this intricate landscape, ensuring compliance throughout the product lifecycle. This support streamlines the regulatory approval process, accelerating market entry.
Key Market Challenges
High Costs
The development and manufacturing of advanced therapies, such as ATMPs (Advanced Therapy Medicinal Products), are inherently resource-intensive. These therapies require significant investment in research and development, with cutting-edge technology and highly specialized expertise necessary for their creation. The costs associated with preclinical and clinical trials, regulatory approvals, and the production of these therapies can often be prohibitively high, which poses a challenge for Contract Development and Manufacturing Organizations (CDMOs) involved in the production process. Furthermore, the advanced nature of these products demands high-quality standards, specialized facilities, and skilled personnel to ensure safety, efficacy, and compliance with stringent regulations. CDMOs must find innovative ways to streamline production processes, optimize resource allocation, and implement cost-control strategies without compromising the quality of the therapies being developed. Balancing cost efficiency while meeting the demands for high-end manufacturing processes is a critical challenge in the ATMP sector, and finding sustainable solutions is key to ensuring the long-term success of these products.
Key Market Trends
Increased Collaboration and Partnerships
Collaboration is increasingly becoming a critical driver of innovation within the Advanced Therapy Medicinal Product (ATMP) sector. As the complexity and scope of these therapies continue to grow, Contract Development and Manufacturing Organizations (CDMOs) are recognizing the importance of strategic partnerships with pharmaceutical companies, biotech startups, and academic institutions. These alliances allow stakeholders to pool resources, share knowledge, and co-develop cutting-edge therapies that may otherwise be challenging to create independently. In February 2022, Recipharm AB successfully finalized its acquisition of Vibalogics. Through this arrangement, Recipharm is set to gain valuable expertise in biologics, harnessing Vibalogics' capabilities in areas such as viral vaccines, oncolytic viruses, and gene treatments using viral vectors. This strategic move is expected to provide Recipharm with a substantial diversification of its offerings across various technologies and modalities.
Key Market Players
Celonic AG
Rentschler Biopharma SE
Catalent, Inc.
Lonza Group AG
WuXi Advanced Therapies
Minaris Regenerative Medicine, LLC
Pluri Biotech Ltd.
REPROCELL USA Inc.
BioPhorum Operations Group
Cellares Corporation
Report Scope:
In this report, the Global Advanced Therapy Medicinal Products CDMO Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Advanced Therapy Medicinal Products CDMO Market, By Product:
Gene Therapy
Cell Therapy
Tissue Engineered
Others
Advanced Therapy Medicinal Products CDMO Market, By Phase:
Phase I
Phase II
Phase III
Phase IV
Advanced Therapy Medicinal Products CDMO Market, By Indication:
Oncology
Cardiology
Central Nervous System
Musculoskeletal
Infectious disease
Immunology & inflammation
Others
Advanced Therapy Medicinal Products CDMO Market, By Region:
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Asia-Pacific
China
Japan
India
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Advanced Therapy Medicinal Products CDMO Market.
Available Customizations:
Global Advanced Therapy Medicinal Products CDMO market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Advanced Therapy Medicinal Products CDMO Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product (Gene Therapy, Cell Therapy, Tissue Engineered, Others)
5.2.2. By Phase (Phase I, Phase II, Phase III, Phase IV)
5.2.3. By Indication (Oncology, Cardiology, Central Nervous System, Musculoskeletal, Infectious disease, Immunology & inflammation, Others),
5.2.4. By Region
5.2.5. By Company (2024)
5.3. Market Map
6. North America Advanced Therapy Medicinal Products CDMO Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product
6.2.2. By Phase
6.2.3. By Indication
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Advanced Therapy Medicinal Products CDMO Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Product
6.3.1.2.2. By Phase
6.3.1.2.3. By Indication
6.3.2. Canada Advanced Therapy Medicinal Products CDMO Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Product
6.3.2.2.2. By Phase
6.3.2.2.3. By Indication
6.3.3. Mexico Advanced Therapy Medicinal Products CDMO Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Product
6.3.3.2.2. By Phase
6.3.3.2.3. By Indication
7. Europe Advanced Therapy Medicinal Products CDMO Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product
7.2.2. By Phase
7.2.3. By Indication
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Advanced Therapy Medicinal Products CDMO Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Product
7.3.1.2.2. By Phase
7.3.1.2.3. By Indication
7.3.2. United Kingdom Advanced Therapy Medicinal Products CDMO Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Product
7.3.2.2.2. By Phase
7.3.2.2.3. By Indication
7.3.3. Italy Advanced Therapy Medicinal Products CDMO Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Product
7.3.3.2.2. By Phase
7.3.3.2.3. By Indication
7.3.4. France Advanced Therapy Medicinal Products CDMO Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Product
7.3.4.2.2. By Phase
7.3.4.2.3. By Indication
7.3.5. Spain Advanced Therapy Medicinal Products CDMO Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Product
7.3.5.2.2. By Phase
7.3.5.2.3. By Indication
8. Asia-Pacific Advanced Therapy Medicinal Products CDMO Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product
8.2.2. By Phase
8.2.3. By Indication
8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Advanced Therapy Medicinal Products CDMO Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Product
8.3.1.2.2. By Phase
8.3.1.2.3. By Indication
8.3.2. India Advanced Therapy Medicinal Products CDMO Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Product
8.3.2.2.2. By Phase
8.3.2.2.3. By Indication
8.3.3. Japan Advanced Therapy Medicinal Products CDMO Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Product
8.3.3.2.2. By Phase
8.3.3.2.3. By Indication
8.3.4. South Korea Advanced Therapy Medicinal Products CDMO Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Product
8.3.4.2.2. By Phase
8.3.4.2.3. By Indication
8.3.5. Australia Advanced Therapy Medicinal Products CDMO Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Product
8.3.5.2.2. By Phase
8.3.5.2.3. By Indication
9. South America Advanced Therapy Medicinal Products CDMO Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product
9.2.2. By Phase
9.2.3. By Indication
9.2.4. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Advanced Therapy Medicinal Products CDMO Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Product
9.3.1.2.2. By Phase
9.3.1.2.3. By Indication
9.3.2. Argentina Advanced Therapy Medicinal Products CDMO Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Product
9.3.2.2.2. By Phase
9.3.2.2.3. By Indication
9.3.3. Colombia Advanced Therapy Medicinal Products CDMO Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Product
9.3.3.2.2. By Phase
9.3.3.2.3. By Indication
10. Middle East and Africa Advanced Therapy Medicinal Products CDMO Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Product
10.2.2. By Phase
10.2.3. By Indication
10.2.4. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Advanced Therapy Medicinal Products CDMO Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Product
10.3.1.2.2. By Phase
10.3.1.2.3. By Indication
10.3.2. Saudi Arabia Advanced Therapy Medicinal Products CDMO Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Product
10.3.2.2.2. By Phase
10.3.2.2.3. By Indication
10.3.3. UAE Advanced Therapy Medicinal Products CDMO Market Outlook
